Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593286 | 0.90 | TSHR (0.50) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL16447410 | 0.88 | TSHR (0.48) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| (Chloromethyl)Benzene SCHEMBL9245547 | 0.82 | TRPA1 (0.44) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| SCHEMBL8757082 | 0.81 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| SCHEMBL1302289 | 0.81 | TSHR (0.52) | TSHRALDH1A1ADRA2BADRA2CSLC6A2 | |
| (Chloromethyl)Benzene SCHEMBL5802694 | 0.80 | TRPA1 (0.48) | TSHRSLC6A2SLC6A3CYP2D6CYP2C9 | |
| SCHEMBL3403185 | 0.78 | BCHE (0.49) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| SCHEMBL23499216 | 0.77 | TSHR (0.45) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| SCHEMBL8950839 | 0.76 | TSHR (0.44) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C | |
| SCHEMBL8950842 | 0.76 | TSHR (0.44) | TSHRALDH1A1SMN1; SMN2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3000833-B1 | MICELLES COMPRISING A TRIBLOCK COPOLYMER AND A THERAPEUTIC AGENT | INTEZYNE TECH INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20170240703-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9499665-B2 | Block copolymers for stable micelles | INTEZYNE TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-3000833-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | Intezyne Technologies Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2660255-B1 | Block copolymers for stable micelles | INTEZYNE TECHNOLOGIES INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2660255-A1 | Block copolymers for stable micelles | Intezyne Technologies Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2013154774-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| US-8524783-B2 | Polymer micelles containing anthracylines for the treatment of cancer | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2012058552-A1 | IRON STABILIZED POLYMER MICELLES FOR DRUG DELIVERY APPLICATIONS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-05-03 | — | — | WO | disclosed |
| EP-2427176-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | Intezyne Technologies Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2424359-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | Intezyne Technologies Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110142950-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010129581-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127271-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | MUC1, MSN, SNX9 | TSHR 3451/4885ALDH1A1 3817/4885SMN1; SMN2 554/4885 |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | TSHR 4502/4885ALDH1A1 3679/4885SMN1; SMN2 2070/4885 |
| US-20110142950-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | TSHR 4502/4885ALDH1A1 3679/4885SMN1; SMN2 2070/4885 |
| US-20170240703-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | TSHR 3260/4885ALDH1A1 4634/4885SMN1; SMN2 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.